In 2016, Washington State Governor Jay Inslee appointed a man to the Board of Directors of the Andy Hill Cancer Research Endowment (CARE) Fund. That man was Frederick R. Appelbaum, a physician whose career had already been defined by a single, transformative procedure: autologous bone marrow transplantation.
That appointment is the concrete detail that anchors Appelbaum’s long arc in cancer research. It was not a ceremonial nod. The CARE Fund was established to push money into cutting-edge cancer therapy development. Inslee’s pick signaled that Appelbaum was the person to decide where that money went. The governor chose a researcher who had already changed the field once.
Appelbaum’s change came with the first clinical trial demonstrating autologous bone marrow transplantation. Before that trial, the technique was an idea. After it, it became a pathway. The procedure involves a patient’s own bone marrow cells being harvested, treated, and then returned to the body. It sidesteps the rejection problems of donor transplants. It opened a door that had been locked.
The medical community recognized those contributions on March 15, 2024. But the recognition is less a celebration and more a confirmation. Appelbaum’s work did not stop at the trial. He took the proof and pushed it forward. He kept his focus on finding new and better ways to treat cancer. That focus led to his role on the CARE Fund board.
On that board, Appelbaum did not simply lend his name. He worked to shape the fund’s priorities. He helped decide which research initiatives got resources and which did not. The fund’s goal is to support innovative research. Appelbaum’s job was to identify what was genuinely innovative versus what was merely novel. His experience in the bone marrow trial gave him the authority to make that call.
The result has been progress. The CARE Fund has made significant strides in recent years. That is a direct line from Appelbaum’s leadership. He brought a researcher’s skepticism and a physician’s urgency to the boardroom. He understood that a promising lab finding might fail in a patient. He also understood that a failed trial could still teach something valuable. His knowledge guided the fund’s resources toward the most likely breakthroughs.
Appelbaum’s own breakthrough—the autologous bone marrow transplant—has done more than treat patients. It has inspired a new generation of researchers. They saw what he did and they are following his path. They are looking for the next locked door and the next key.
The lives saved by his technique are not a statistic in a report. They are the measure of a career. Appelbaum, as a physician and writer, has documented that career. He has written about the science and the human cost of cancer. He has not stopped working.
The Andy Hill Cancer Research Endowment Fund carries the name of a Washington State senator who died of cancer. Appelbaum was appointed to its board in 2016. He has been there ever since, applying the same discipline he used in the clinic. He does not chase headlines. He chases results.
On March 15, 2024, the medical community took a moment to look back at what Appelbaum has done. The view is clear. He took a risky idea—autologous bone marrow transplantation—and proved it could work. He then took that proof and used it to steer a state fund toward the next generation of treatments. That is the whole story. One trial. One appointment. Decades of work.
